FDA & Government News
FDA Drops Warning From GLP-1 RAs
-
By
January 13, 2026
-
3 min
-
1
FDA meta-analysis showed no link between GLP-1 RAs and suicidal behavior.
-
2
Saxenda, Wegovy, Zepbound to update labeling.
-
3
Study involved 107,910 patients across 91 trials.
-
4
GLP-1 RAs aid in weight loss without increased psychiatric risks.
-
5
FDA investigates after initial post-marketing reports raised concerns.
-
The US FDA has conducted a meta-analysis of 91 placebo-controlled trials involving over 107,000 patients and found no correlation between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidal ideation or behavior. This finding has led to the conclusion that medications such as Saxenda, Wegovy, and Zepbound, previously labeled with warnings related to psychiatric risks, do not pose such threats. The FDA's request for new labeling aims to standardize the safety messages across all GLP-1 RAs, following ongoing evaluations and retrospective studies, confirming their safety for patients dealing with obesity and diabetes.
-
1
FDA meta-analysis showed no link between GLP-1 RAs and suicidal behavior.
-
2
Saxenda, Wegovy, Zepbound to update labeling.
-
3
Study involved 107,910 patients across 91 trials.
-
4
GLP-1 RAs aid in weight loss without increased psychiatric risks.
-
5
FDA investigates after initial post-marketing reports raised concerns.
Listen Tab content
